Engineer – Combination Product Development, Prefilled Syringe (PFS) Platform
Amgen is hiring for Engineer – Combination Product Development, Prefilled Syringe (PFS) Platform in US - California - Thousand Oaks. Mid level, $88k–$119k a year stated. First seen November 5, 2026; open as of November 12, 2026. Jobs taken straight from company career pages — no aggregator in between.
With Destava: How well do you fit? · Tailor my résumé · Write a cover letter
- Company
- Amgen
- Where
- US - California - Thousand Oaks
- Level
- Mid
- Pay stated
- $88k–$119k a year
- First seen
- November 5, 2026
- Listed via
- Workday
What the posting says
Career Category Engineering Job Description Join Amgen’s Mission of Serving Patients At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients living with serious illnesses—drives all that we do. Since 1980, we’ve helped pioneer the world of biotech in our fight against the world’s toughest diseases. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat heart disease, obesity and obesity-related conditions, rare diseases, inflammatory conditions and cancer. As a member of the Amgen team, you’ll help make…
Read more and apply on Amgen's site
More jobs like this
Senior R&D Engineer
Save to applyEngineer II Product Analysis
Save to applySenior Scientist II, Recombinant Peptide Process Development
Save to applyClinical Engineer 846001
Save to apply
See all 14 Bioengineers and Biomedical Engineers jobs in Los Angeles
A search agent finds the jobs this list misses: the ones that mean the same without the same words. Have Destava watch for engineer – combination product development, prefilled syringe (pfs) platform jobs in US - California - Thousand Oaks, new matches every morning on your own account.
This page includes information from the O*NET 31.0 Database by the U.S. Department of Labor, Employment and Training Administration (USDOL/ETA). Used under the CC BY 4.0 license. O*NET® is a trademark of USDOL/ETA.